Forhumanity provides VigorAir, a prescription‑only inhaled sildenafil formulation delivered via a breath‑activated dry‑powder inhaler for on‑demand treatment of erectile dysfunction. The 25 mg capsule is inhaled shortly before sexual activity, offering faster systemic absorption and onset compared with oral PDE5 inhibitors, while being compounded under §503A for individualized patient dosing.
Funding
Funding not disclosed
Founders
Product
Problem
Men with erectile dysfunction often rely on oral PDE5 inhibitors that require ingestion and a relatively long onset time, limiting spontaneity and convenience for on-demand sexual activity.
Solution
Forhumanity offers VigorAir, a compounded prescription of inhaled sildenafil delivered via a breath‑activated dry‑powder inhaler. A single 25 mg capsule is inhaled shortly before sexual activity, providing rapid systemic absorption and faster onset of effect compared with traditional oral tablets. The formulation is prepared under §503A for individual patients, allowing personalized dosing while maintaining prescription control. By using an inhalation route, VigorAir aims to reduce the delay between dosing and erection, supporting more spontaneous sexual experiences for men with ED.
Target Audience
Primary customers are adult male patients diagnosed with erectile dysfunction who seek a fast‑acting, on‑demand treatment option and have access to a prescribing clinician.
Features
- Single-use 25 mg sildenafil capsule designed for inhalation only with a dry‑powder inhaler
- Breath‑activated delivery system that releases medication upon inhalation for rapid absorption
- On‑demand dosing intended to be taken shortly before sexual activity, not for continuous daily use
- Compounded under §503A, enabling patient‑specific formulation and prescription oversight
- Includes safety warnings for contraindications such as nitrate use, certain cardiovascular conditions, and severe milk‑protein allergy due to lactose in the powder
- Provides standard side‑effect profile of sildenafil with additional guidance on inhalation‑related respiratory considerations